CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth...
Hence then, the article about kelun biotech presents positive phase 3 data for trastuzumab botidotin compared to t dm1 at 2025 esmo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO )
Also on site :
- Egypt solidifies 2030 World Cup roadmap with Mohamed Salah and Ibrahim Hassan
- Mumbai rain havoc: Schools and colleges shut on Monday; flights hit, roads flooded
- Cunard Makes History With a 178-Year New York Tradition at America’s 250th Celebration